Top 2 Health Care Stocks That May Collapse This Quarter
Portfolio Pulse from Avi Kapoor
Terns Pharmaceuticals and Immunovant are two health care stocks that may face short-term declines due to being overbought, as indicated by their high RSI values. Both companies have recently reported positive trial results, leading to significant stock gains.
September 09, 2024 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Immunovant's stock is overbought with an RSI of 72.34, indicating potential short-term decline despite recent gains from positive trial results.
The RSI of 72.34 suggests Immunovant is overbought, which often leads to a price decline. The recent 17% gain from positive trial results may not sustain the stock's momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Terns Pharmaceuticals' stock is overbought with an RSI of 73.09, indicating potential short-term decline despite recent gains from positive trial results.
The RSI of 73.09 suggests Terns Pharmaceuticals is overbought, which often precedes a price decline. The recent 19% gain from positive trial results may not sustain the stock's momentum.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100